MedTrace Logo

Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART

NCT00196612 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2005-09-20

No results posted yet for this study

Summary

The combination of two nucleoside analogues and one protease inhibitor is a highly active antiretroviral therapy (HAART) in HIV infected adults. In those with an undetectable viral load, a once daily combination of FTC, ddI, efavirenz would be easier to take, with less side effects and the same efficacy. The aim of the study was to evaluate if the once daily combination presents the same efficacy than the HAART therapy with less side effects and a better adherence.

Conditions

  • HIV Infections

Interventions

DRUG

emtricitabine, FTC (drug)

DRUG

didanosine, ddI (drug)

DRUG

efavirenz (drug)

Sponsors & Collaborators

  • Triangle Pharmaceuticals

    collaborator INDUSTRY

  • Gilead Sciences

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Dupont Applied Biosciences

    collaborator INDUSTRY

  • French National Agency for Research on AIDS and Viral Hepatitis

    lead OTHER_GOV

Principal Investigators

  • Jean-Michel Molina, MD, PhD · Service de Maladies Infectieuses, Hôpital Saint-Louis, Paris, 75475, France

  • Genevieve Chene, MD, PhD · INSERM unité 593, Bordeaux, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Completion
2004-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00196612 on ClinicalTrials.gov